Settlement Gives Celltrion Date For US Higher-Strength Humira Biosimilar
Plans Q3 2023 Launch For Yuflyma 100mg/ml Citrate-Free Version Of Adalimumab
Celltrion has secured a US launch date for its higher-strength adalimumab biosimilar, Yuflyma, through a settlement with AbbVie. However, the company will face a number of other Humira rivals in 2023.
You may also be interested in...
Samsung Bioepis and Organon have broken new ground for Humira biosimilars in the US after receiving the first FDA approval for a higher-strength 100mg/ml adalimumab biosimilar.
Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker